{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:12:37Z","timestamp":1791177157295,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhepr.2026.101915","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:37:43Z","timestamp":1781224663000},"page":"101915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical predictors of response to atezolizumab\/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma"],"prefix":"10.1016","volume":"8","author":[{"given":"Anne-Victoire","family":"Odent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-782X","authenticated-orcid":false,"given":"Claudia","family":"Campani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3919-4135","authenticated-orcid":false,"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-3182","authenticated-orcid":false,"given":"Yann","family":"Touchefeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Delhoume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rosmorduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-3726","authenticated-orcid":false,"given":"Alina","family":"Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-4124","authenticated-orcid":false,"given":"Han Chu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-9406","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2554-1877","authenticated-orcid":false,"given":"Giuliana","family":"Amaddeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-8551","authenticated-orcid":false,"given":"Massih","family":"Ningararhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5254-2464","authenticated-orcid":false,"given":"Isabelle","family":"Olivier-Hourmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Metivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-3939","authenticated-orcid":false,"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Ntandja-Wandji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Ozenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sidali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2287-0635","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Hollande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7351-5027","authenticated-orcid":false,"given":"Nathalie","family":"Ganne-Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Nahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Peron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lequoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Trepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-5122","authenticated-orcid":false,"given":"Sarah","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-9353","authenticated-orcid":false,"given":"Jean-Charles","family":"Nault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101915_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101915_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.101915_bib3","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101915_bib4","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/gutjnl-2025-334928","article-title":"Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction","volume":"74","author":"Pinter","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101915_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101915_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101915_bib7","article-title":"The ALBI score: from liver function in patients with HCC to a general measure of liver function","volume":"4","author":"Toyoda","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101915_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101915_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/HEP.0000000000000030","article-title":"Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis","volume":"77","author":"El Hajra","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101915_bib10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","article-title":"Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction","volume":"10","author":"Fulgenzi","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2026.101915_bib11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for Child-Pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2026.101915_bib12","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1007\/s00432-023-04678-2","article-title":"Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients","volume":"149","author":"Rimini","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101915_bib13","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-25-0495","article-title":"Subset of Child-Pugh score 7 shows comparable survival outcomes to Child-Pugh score 6 in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab","volume":"31","author":"Lee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101915_bib14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D\u2019Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101915_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70337","article-title":"Real-world outcomes of atezolizumab-bevacizumab in hepatocellular carcinoma: the prospective French CHIEF cohort","volume":"45","author":"Allaire","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101915_bib16","article-title":"Efficacy and safety of atezolizumab plus bevacizumab for patients with hepatocellular carcinoma and Child-Pugh class B","volume":"46","author":"Sasaki","year":"2026","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101915_bib17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101915_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101915_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/MEG.0000000000002830","article-title":"Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study","volume":"36","author":"Adhoute","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101915_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/HEP.0000000000000636","article-title":"Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab","volume":"79","author":"Campani","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101915_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","article-title":"Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death","volume":"31","author":"Cabibbo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101915_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101915_bib23","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.cgh.2024.12.028","article-title":"Liver decompensation in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a real-life study","volume":"23","author":"Stella","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101915_bib24","article-title":"Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies","volume":"6","author":"Campani","year":"2024","journal-title":"JHEP Rep"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:19:17Z","timestamp":1790111957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589555926001862"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101915","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical predictors of response to atezolizumab\/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101915"}}